Novo in major phase III setback
![Foto: Jens Lindhe](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article6943017.ece/ALTERNATES/schema-16_9/Novo%2520Nordisk%2520hovedkvarter.jpg)
Disappointment is the overriding sensation for Novo Nordisk after it submitted fresh headline data from a phase III study with its drug Victoza (liraglutide) to treat patients with type 1 diabetes – and the Danish-based group takes the consequence of the disappointing trial, at least for now.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s Victoza left out of Express list once again
For abonnenter
Rival data could increase pressure on Novo
For abonnenter
Analyst: Novo’s product is superior, but…
For abonnenter